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Introduction
This chapter explores the ethical implica-
tions of genetically modified organisms 
(GMOs) in food that originate from plants 
genetically altered through bioengineering. 
The tensions between the proliferation of 
agricultural biotechnology and consumer 
concerns about potential harm to human 
health and the environment ultimately cause 
us to reflect on the current regulatory scheme 
in the USA. Does the failure to require ade-
quate, meaningful labeling, and the preemp-
tion of grassroots efforts to do so, violate 
our right to informed consent by not allow-
ing consumers a choice as to whether to 
knowingly and willingly assume the risks of 
ingesting GMOs?
Genetically modified (GM) plants involve 
a uniquely invasive application of agricultur-
al biotechnology, unlike traditional plant 
breeding and hybrid methods used in the 
past. Through this novel process, the DNA of 
one organism is inserted into another, caus-
ing the target trait to be expressed in that 
non-related species at the cellular level 
throughout the plant, including the fruit or 
vegetable and the component ingredients 
that become part of a variety of food prod-
ucts. Most commonly, GM plants are engi-
neered to withstand a weed-killing pesticide, 
Roundup, sold by Monsanto along with the 
herbicide-resistant varieties of soybeans, 
canola, cotton, corn, radicchio, rice and sug-
ar beet. In addition, genes derived from a 
bacterium in the soil used as an insecticide, 
Bacillus thuringiensis (Bt), have been insert-
ed into crops to induce the plant to produce 
a toxin against certain insects, producing Bt-
corn, Bt-cotton, Bt-potatoes, Bt-rice and 
Bt-tomatoes (Strauss, 2006).
There is even a biotechnology invention, 
as yet undeveloped for commercial use due 
to widespread consumer opposition in the 
international community, called the ‘Termi-
nator’ gene, also known as Genetic Use 
Restriction Technologies (GURTs). Developed 
jointly by the agricultural biotechnology 
industry and the United States Department 
of Agriculture (USDA), this technology ge-
netically alters plants to produce sterile 
seeds at harvest, effectively blocking the 
ability of the plant to procreate future gener-
ations in order to prevent farmers’ traditional 
practice of saving and replanting harvested 
seed and thereby necessitating the purchase 
of new seeds from the biotechnology com-
pany each year (Strauss, 2009). Recogniz-
ing the conceivable catastrophic effect on 
the global food supply if spread via com-
mon cross-pollination, the United Nations, 
through the UN Convention on Biological 
Diversity in 2000, implemented and has 
continued to maintain a de facto moratorium 
on these sterile seed technologies (Convention 
on Biological Diversity, 2017). Ultimately, 
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the very existence of the Terminator serves 
as a reminder that there is virtually no limit 
as to what might be developed in the future 
through this novel technology.
In the USA, GM crops now comprise al-
most all of the plantings and the vast major-
ity of component products in the US market 
(Strauss, 2012a). Recent statistics indicate 
that GM crops accounted for 94% of soy-
beans, 92% of corn and 96% of cotton plant-
ed in 2017; and GM canola, squash, papaya, 
alfalfa and sugar beet were widely planted 
(USDA, 2017a). The Grocery Manufactur-
ers Association (GMA) reported in 2005 
that 75% of all processed foods in the USA 
contained a GM ingredient, including al-
most every product with a corn or soy 
 ingredient and some with canola or cotton-
seed oil; this figure has continued to be 
widely cited. However, projecting from the 
exponentially higher plantings since then, 
the prevalence should be substantially 
higher today. The current GMA position 
statement emphasizes the proliferation of 
GMOs:
It is important for our consumers to know 
that this technology is not new. In fact, it 
has been around for the past 20 years, and 
today, 70–80% of the foods we eat in the 
United States, both at home and away 
from home, contain ingredients that have 
been genetically modified. If the ingredient 
label on any food or beverage product 
contains corn or soy, they most likely 
contain genetically modified ingredients, 
as a very high percentage of those crops 
grown in the U.S. use GM technology. In 
addition, a high percentage of other 
ingredients in the U.S., such as sugar 
beets, are grown with the use of GM 
technology as well. (2017, n.p.)
Yet the widespread use of GMOs is un-
known to most consumers because, unlike the 
European Union and the broader internation-
al community where more than 60 countries 
require labeling, the USA does not dictate 
mandatory labeling, rigorous approval or 
monitoring of GM plants and foods (Strauss, 
2006; Consumer Reports, 2014). Moreover, 
due to the absence of long-term studies, the 
level of safety and the effect on human health 
and the environment remain uncertain.
Surveys on GM foods reveal that a signif-
icant majority of consumers believe that the 
government should include ethical and moral 
considerations when making regulatory deci-
sions about genetic engineering. Moreover, 
consumers seek an active role from regula-
tors to ensure that new products are safe 
(Strauss, 2007). Consumer polls uniformly 
demonstrate that a vast majority of US citi-
zens would like GMOs to be labeled (Center 
for Food Safety, 2017). For instance, a recent 
Consumer Reports National Research Center 
survey found that 92% of Americans prefer 
GM foods to be labeled and more than 70% 
indicated that they do not want GMOs in 
their food (Consumer Reports, 2014). This is 
a critical area where examining the ethical 
implications can lead to further developments 
in the law as a means for the community to 
address and resolve these issues.
The juxtaposition between the prolifera-
tion of agricultural biotechnology and con-
sumer concerns will be explored in view of 
the critical role of food safety in human 
health and the environment. To this end, the 
next section examines the key ethical issues 
arising from genetic engineering, particularly 
the right to informed consent and conflicts 
of interest in studies and scientific research 
that may hamper inquiry into the possible 
long-term risks. The chapter then analyzes 
the new federal statute recently passed in 
the USA purportedly to label these foods 
and evaluates whether in fact it does so in an 
effective and meaningful way to fulfill these 
consumers’ rights. The chapter highlights an 
approach that takes into account these ethi-
cal tensions and shifts the dialogue from 
public outcry to the policy and regulation 
arena. Accordingly, this proposal embraces 
participation of all stakeholders, education 
of the public on the potential risks, develop-
ment of comprehensive labeling to enable 
informed consumer choice and establishment 
of a more active and independent role for 
government agencies in regulating biotech-
nology companies. The chapter concludes by 
providing queries to assist policy makers in 
implementing a new regulatory framework 
in the USA, recognizing that consideration 
be given to ethical tensions in shaping the 
international policy arena.
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Ethical Tensions in Connection 
with GMOs
To recognize an ethical perspective in the 
ongoing discussions about GMOs, the Food 
and Agriculture Organization of the United 
Nations (FAO) formed an expert panel on 
ethics in food and agriculture, which met in 
four sessions and issued reports on specific 
focus areas (FAO, 2007a). The first report of 
the FAO panel, ‘Ethical issues in food and 
agriculture’, introduced ethical questions 
related to its mandate, such as: What is the 
value of food? What is the value of human 
health? What is the value of nature and nat-
ural resources? The FAO panel recognized as 
principles the right to adequate food, optimi-
zation, trust, equity and informed consent 
in identifying these ethical concerns as central 
to the debate about the future (FAO, 2001a).
The FAO’s second report, ‘Genetically 
modified organisms, consumers, food safe-
ty and the environment’, stressed the role 
of ethical considerations in food and agri-
culture with regard to GMOs as well as food 
safety and the environment (FAO, 2001b). 
Issues examined included ownership of the 
necessary tools to produce GMOs, potential 
consequences of their use and undesirable 
effects that could result from their appli-
cation, both now and in the future. Most 
 important, the report advocated the partici-
pation of all stakeholders in making deci-
sions regarding GMOs, emphasizing that 
‘[w]idely communicated, accurate and objec-
tive assessments of the benefits and risks 
associated with the use of genetic technol-
ogies should involve all stakeholders . . . 
Experts have the ethical obligation to be 
proactive and to communicate in terms 
that can be understood by the lay person’ 
(2001b, p. 25).
The FAO’s third report delved further into 
the risks of GMOs and the ethical imperative 
to make human health and the environment 
the paramount concern and accordingly re-
strict the use of this technology:
Genetic engineering introduces a new 
uncertainty, as it affects the genetic design of 
plants and animals and thus the composition 
of our food. The Panel reiterated the concern 
expressed in its earlier sessions over the 
potential environmental, health and 
socio-economic impacts of genetic 
engineering and genetically modified 
organisms (GMOs). Unless there is an 
overriding advantage that is apparent, the 
Precautionary Principle, which is the 
foundation of the Cartagena Protocol on 
Biosafety, would point to a preference for 
non-genetically engineered food. Even when 
there is an obvious advantage, an exhaustive 
testing of the safety of the genetically 
engineered food is required. (2005, p. 4)
In its fourth and final report, the FAO 
continued to emphasize
the ethical requirement to avoid the  
risks of, while sharing the benefits of, 
biotechnologies as part of the advancement 
of science, which also involves an  
examination of the ethical issues related to 
intellectual property rights . . . Ethical 
considerations of decision-making in relation 
to genetically modified organisms from the 
perspective of the consumer, food safety and 
the environment are closely related to this 
issue. (2007b, p. 10)
Thus, a discussion of ethical tensions is war-
ranted in the public arena, and all of the 
stakeholders should have a voice in deter-
mining the policy decisions that conse-
quently ensue.
These considerations have induced the 
European Union and other countries in ac-
cordance with the precautionary principle to 
limit the use of bioengineered foods and re-
quire labeling of foods with GM ingredients. 
The continued development of genetically 
modified plants raises several moral princi-
ples, such as respect for nature and the value 
of life; consideration of the environment; 
and equity, power and the economically disad-
vantaged (Strauss, 2007). The most signifi-
cant ethical tensions will be explored further 
below: the right to informed consent and 
the latent impact of conflicts of interest in 
scientific research.
The right to informed consent
The foregoing reluctance of the US govern-
ment to establish a rigorous labeling scheme 
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for the treatment of GM crops and GMOs in 
food raises critical ethical tensions. For 
consumers, the lack of clear and meaningful 
disclosure of the fact that their food was 
developed using bioengineering techniques 
violates the right of informed consent. From 
an ethical perspective, particularly a Kantian 
model, US citizens have been deprived of their 
autonomy and freedom of choice (Strauss, 
2007). Individuals have the fundamental 
right to know what they are buying and eat-
ing before making a purchasing decision.
An economic model also supports trans-
parency and disclosure of this information 
(Brussel, 2003). According to this reasoning, 
‘the market for GMOs at both the consumer 
and producer level is unable to achieve a ra-
tional, efficient and socially optimal result 
due to asymmetrical information’ (p. 430). 
Without adequate information, consumers 
cannot make rational decisions about 
whether to purchase and consume GMOs, 
farmers do not have the tools to negotiate 
with biotech seed producers and organic 
farmers cannot effectively allocate resources 
to protect their crops from contamination 
by genetic drift. This market can only func-
tion efficiently
if a mechanism is established for ensuring that 
rational, scientifically-based information on 
the effects of GMOs on human health, 
agricultural production, and the environment 
is available to the public. Because transaction 
costs would be prohibitively high for 
individual consumers or farmers to obtain 
such information, a system of mandatory 
disclosures tied to discretionary participation 
in the market for GMOs should be established 
by the government. (Brussel, p. 432)
The government has a responsibility to 
protect its citizens, particularly in such a criti-
cal area as the safety of the food supply. As a 
matter of ethics, the as yet unknown risks 
must not be placed on the unsuspecting pub-
lic rather than on the companies who have 
created these genetic modifications. To do so 
would betray consumers’ trust in their gov-
ernment to ensure their health and well-being 
as fiduciaries acting on their behalf. The Food 
and Drug Administration (FDA) has recog-
nized this mandate in its regulatory approach 
to other areas of the food supply, for example, 
applying a zero-risk policy to prohibit the in-
troduction into the food supply of food and 
color additives determined to cause cancer in 
laboratory animals (Strauss, 1987).
Moreover, in an area where the FDA per-
ceives there to be no safety risk – food treated 
with ionizing radiation – it has nonetheless 
required mandatory labeling of such foods, 
with the international (Radura) symbol for 
radiation along with the statement ‘Treated 
with radiation’ or ‘Treated by irradiation’ on 
the food label (FDA, 2016). In mandating a 
disclosure on all irradiated foods, the FDA 
was cognizant of widespread consumer con-
cerns about food irradiation. According to 
the agency, ‘the large number of consumer 
comments requesting retail labeling attest 
to the significance placed on such informa-
tion by consumers’ (Strauss, 2006, p. 184; 
United States, 2012). Yet the FDA has not 
applied this reasoning for GMOs in food, 
where only nonbinding recommendations 
for voluntary labeling have been its policy 
(FDA, 2015).
Consumers have the right to choose what 
they eat, and informed choice can only be 
realized through mandatory labeling on the 
package that is accessible and understanda-
ble. According to Consumers International, 
consumers’ desires and opinions should be 
respected due to a fundamental right to know 
and make informed decisions (Halloran and 
Hansen, 1999). For example, a lack of labe-
ling as to the presence of an introduced gene 
removes the individual’s right to avoid 
known allergens and control their own fate. 
Eight percent of children in the USA have 
food allergies, some of which can be fatal 
(Kolehmainen, 2001). When Pioneer Hi-
Bred spliced Brazil nut genes into a soybean 
to improve its protein content, the altered 
soybean provoked severe allergic attacks in 
eight individuals sensitive to Brazil nuts but 
not soybeans (Nordlee et al., 1996). Without 
a label alerting consumers that a soybean 
could contain genes from a highly allergic 
nut, even individuals aware of their severe 
allergies would have no warning. As a matter 
of policy, vital information about the trans-
genic processing must be made available to 
those individuals who could be affected by 
important health risks (Nestle, 1996).
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While the potential risks generate a need 
for labeling of the presence of GMOs, such 
an approach is also required beyond safety 
issues, as a matter of taste and preference 
and for many health-related reasons. It must 
be recognized that many consumers make 
food choices based on religious, ethical and 
environmental considerations, for example, 
deciding not to eat veal, mass-produced 
chickens or non-organic produce. If biotech-
nology raises similar ethical, health and en-
vironmental concerns, it is not irrational for 
people to act on these preferences and aver-
sions to risk (Teitel and Wilson, 1999). In 
order to make these informed decisions, 
food products must be effectively labeled. As 
a matter of ethics and public policy, ‘[s]ince 
labeling laws are created to meet consumer 
needs, consumer opinion should be respect-
ed’ (Halloran and Hansen, 1999, n.p.).
The decision to allow the public to consume 
unlabeled genetically engineered (GE) food 
strikes some people as ‘grossly undemocratic 
and slanted too far in favor of corporate inter-
ests’. ‘Should our society allow the purported 
commercial rights of a corporation to super-
sede the citizen’s right to make informed 
decisions in the marketplace?’ (Teitel and 
Wilson, p. 61). ‘Every person has a right to 
make choices about what they eat. Every per-
son has a right to know’ (Strauss, 2007, p. 28). 
With an increasing crescendo of proponents, 
this concept has been building momentum as a 
‘Consumer Right to Know’ policy grounded on 
a number of concerns apart from health and 
safety, including religious, ethical, dietary re-
strictions and environmental objections 
(Keane, 2006; Nauheim, 2009; Begley, 2017).
A recent study by the National Academies 
of Sciences (NAS, 2016) provided support for 
labeling of GMOs, not based on safety concerns 
but expressly on the ethical grounds of the con-
sumers’ right to know policies that respect con-
sumer autonomy and fairness, reasoning that: 
‘if non-GE labeling is voluntary, many products 
would have no label information about GE 
content. Consumers would not know whether 
the product contained GE ingredients and 
so would be deprived of the ability to make an 
informed choice about each product’ (2016, 
pp. 305–306). In its most significant state-
ment, the NAS committee concluded:
Mandatory labeling provides the opportunity 
for consumers to make their own personal 
risk-benefit decisions (regardless of the 
regulatory determination of safety) and to 
express a preference for a method of 
production. A voluntary non-GE label places 
the burden on consumers who want to avoid 
GE foods to search for non-GE products and 
provides no information to consumers who 
may not be actively searching for the 
information but who might be informed by 
the label. Voluntary labeling also may not 
help consumers who cannot afford the kinds 
of foods that will be voluntarily labeled. 
(2016, p. 306)
For consumers who are careful about the 
content of the food they eat, choosing or-
ganic foods may be an option, but it is not an 
equitable and practical solution for the ma-
jority of Americans. Organic foods tend to 
be more expensive than non-organic prod-
ucts and they are not available for all types 
of food, stores and areas of the country. 
Thus, most consumers do not have the genu-
ine choice and access to purchase organic 
foods as an alternative to what has previous-
ly been known as ‘traditional’ foods (Strauss, 
2007). Moreover, issues of cross-contamina-
tion increasingly threaten the integrity and 
economic viability of the organic food sup-
ply (WHO, 2005).
The government has the ethical obliga-
tion to protect the safety of the mainstream 
food supply for all of its citizens. The FAO 
expert panel on ethics recognized that:
[t]he right to adequate food, as understood 
today, carries with it obligations on the part 
of states to protect individuals' autonomy 
and capacity to participate in public decision-
making fora, especially when other 
participants are more powerful, assertive or 
aggressive. These obligations can include the 
provision of public resources to ensure that 
those fora take place in a spirit of fairness 
and justice. (2001b, p. 25)
The FAO second report concluded that 
this right has not been fulfilled in connec-
tion with genetically engineered products. 
The most important stakeholders have been 
excluded from the process because:
[c]itizens have a direct interest in  
technological developments, yet there are 
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obstacles to their participation in  
decision- making that must be acknowledged 
and overcome. The public has not been 
adequately informed about the application of 
gene technology to food production or the 
consequent potential impacts on consumers’ 
health and the environment. (2001b, p. 25)
As a result, with the confusing and conflict-
ing jumble of claims in the media, ‘the public 
is losing faith in scientists and government’ 
(p. 25).
Following similar reasoning, Geoffrey 
Podger, as Executive Director of the Europe-
an Food Safety Authority (EFSA), promoted 
a labeling approach as a means to regain the 
support of the public. He explained that the 
European opposition to GMOs was based on 
ethical grounds as a reaction to being denied 
a choice when GMO and non-GMO varieties 
could not be differentiated. Thus, the European 
regulatory approach arose in part as a solu-
tion to this ethical and practical duty to inform. 
The advantage of labeling is that it provides 
a choice ‘[a]nd while the people who insist on 
choice may be quite a small part of the popu-
lation, they are very vociferous and they are 
often in positions of power and prominence’ 
(Podger, 2004, n.p.). Accordingly, the key to 
public perceptions is a transparent regulato-
ry process that gives people readily available 
information on the science.
The responsibility of government to pro-
tect its citizens and respond to their con-
cerns should necessitate, at the very least, 
mandatory labeling and monitoring of 
GMOs in food. Past studies have found that, 
unlike the Europeans, American consumers 
have generally trusted their government 
and regulatory agencies. Attitudes toward 
the government link closely with public per-
ceptions of biotechnology, press coverage 
and policy formation (Gaskell et al., 1999). 
This fact offers an even greater reason why it 
is critical that the government does not be-
tray that trust in an area as fundamental 
and critical as food safety.
Most recently in the USA, public outrage at 
being denied a choice has generated a grass-
roots political effort to raise consciousness 
of consumers and alert them as to what they 
are not being told, while advocating labeling 
(Justlabelit, no date). At the local, state and 
even federal levels, legislative efforts have 
attempted to respond to the public’s right to 
know, as well as the safety concerns for con-
sumers and farmers. But a review, below, of 
the history and current status of those initi-
atives reveals that these noble goals have 
not yet been satisfactorily achieved.
Conflicts of interest in studies 
and scientific research
Several sources have raised the issue of the 
close connection between the academic com-
munity involved in research and the indus-
tries or patents they seek to develop (Hoffman 
and Sung, 2005). This direct financial stake, 
via stock options or patent participation, 
 creates an inherent conflict of interest. One 
fear is that ‘the lure of profit could color sci-
entific integrity, promoting researchers to 
withhold information about potentially dan-
gerous side-effects’ (Batalion, 2009, n.p.). 
As a result of this conflict of interest and dis-
incentives for long-term studies, the actual 
risks of this novel technology remain largely 
unknown.
Well-funded programs in plant genetics 
and genetic engineering are supplanting 
research to enhance organic methods and 
other low-input alternatives. A 1990 study 
discovered that ‘from [ten percent] up to 
one third of biomedical researchers at pres-
tigious universities such as Stanford and 
MIT had direct corporate ties’ (Tokar, 1999, 
n.p.). With the exponential growth of the
biotechnology industry since then, today’s 
figures are no doubt even higher. These ties 
continue to shift more public funds into pro-
jects that support the research agenda of the 
biotechnology industry.
Some groups have also expressed con-
cern that intellectual property incentives 
limit the development of more beneficial 
genetically engineered crops. In July 2003, 
a coalition of public-sector research institu-
tions announced the formation of the Public- 
Sector Intellectual Property Resource for 
Agriculture (PIPRA) (Atkinson et al., 2003; 
PIPRA, no date). Funded by the Rockefeller 
and McKnight Foundations, PIPRA contends 
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that ‘the benefits of much publicly funded 
research come to private industry through 
university technology transfer programs, 
limiting universities’ flexibility to conduct 
research’ (Hoffman and Sung, 2005, p. 15). 
As a result, biotechnology patents may 
not be utilized for developments with 
little commercial value that would help the 
poor and promote the original goal of food 
security.
Because the research at public institu-
tions is often heavily influenced by the source 
of funding, this predominantly private back-
ing has diverted research time and money 
away from projects that would benefit ‘the 
public good, such as biological control, organ-
ic production systems and general agroeco-
logical techniques’ (Altieri and Rosset, 1999, 
n.p.). This situation has sparked suggestions
that ‘[c]ivil society must request more re-
search on alternatives to biotechnology by 
universities and other public organizations’ 
(1999, n.p.).
Moreover, one of the significant prob-
lems associated with the privatization of 
biotechnology rights is the company’s re-
striction of information.
While the basic realities of modern business 
clearly underscore the need for 
confidentiality, it is also true that 
confidentiality provisions are often used as a 
means of avoiding disclosures. In the face of 
increasing recognition that activities, 
including especially species introduction, in 
one country may have serious impacts on 
neighbouring countries, labelling and other 
access to information is increasingly 
addressed at international and regional 
levels. (Prakash et al., 2011, p. 7)
Sharing of some of this information is crucial 
for risk assessment, long-term studies and 
developing buffer zones between genetically 
engineered and conventional or organic 
crops that would avoid spreading these risks 
exponentially through cross-contamination.
In its recent report, the NAS acknowl-
edged that any new food ‘may have some 
subtle favorable or adverse health effects 
that are not detected even with careful 
scrutiny and that health effects can develop 
over time’ (2016, p. 19). It recommended 
additional public funding for research, 
 particularly in cases where early published 
studies produce ‘equivocal results’ regard-
ing health effects of a GE crop, ‘using trusted 
research protocols, personnel, and publica-
tion outlets to decrease uncertainty and 
increase the legitimacy of regulatory deci-
sions’ (p. 19).
According to one examination of the risks 
and precautions arising from GMOs:
Regulation of GMO deals with a  
transscientific problem, that is, the 
resolution of the problems is beyond the 
competence of the scientific system. Public 
perception and acceptance are dependent on 
trust and whether the products or processes 
benefit them as citizens and consumers. To 
take proper accounts of uncertainties and 
public concern would help to capture the 
benefits, minimize the risk, and provide goals 
for future development and use of genetic 
engineering. (Prakash et al., 2011, p. 11)
Critical to maintaining the public trust will 
be embracing transparency and disclosure 
through a comprehensive and effective labe-
ling policy.
The New DARK Act and Preemption 
of State Initiatives
In the shadow of these ethical tensions 
emerged a new piece of federal legislation 
that extinguished grassroots efforts to re-
quire mandatory labeling of GMOs in the 
USA. Attempts to regulate the safety and 
labeling of GMOs had been raised unsuccess-
fully every year at the federal level through 
bills introduced in Congress that died a quiet 
death in committees. For example, in May 
2002, H.R. 4814 was one of five bills intro-
duced by Representative Dennis Kucinich 
(Democrat-Ohio) that sought to expand the 
regulation of agricultural biotechnology. On 
2 May 2006, Representative Kucinich intro-
duced the ‘Genetically Engineered Food 
Safety Act’ (H.R. 5268, 109th Congress 
2006) and four other bills regarding GMOs 
(Strauss, 2007). Representative Kucinich in-
troduced similar bills in the 111th Congress, 
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including legislation that would have pro-
tected farmers and shifted liability to the 
biotech companies (H.R. 5577, 111th Con-
gress 2010) (Strauss, 2012b). One of the 
most recent efforts, introduced into the US 
Senate on 2 March 2016 by Democratic 
Senators Jeff Merkley, Patrick Leahy, Jon 
Testor and Dianne Feinstein, the ‘Biotech-
nology Food Labeling Uniformity Act’ 
(S. 2621, 114th Congress 2015), would have 
informed consumers of the presence of GM 
ingredients in their food while giving several 
options to food manufacturers for how to 
indicate this information on the Nutrition 
Fact Panel (Merkley, 2016). But this pro-
posed legislation was superseded by the one 
federal bill that did ultimately become law, 
discussed below.
At the state level, momentum for labeling 
appeared to build with the passage of several 
statewide labeling initiatives, which many 
hoped would take hold and lead to a stringent 
mandatory labeling under federal law that 
would follow the states. In 2013, Connecticut 
became the first state to pass legislation for 
labeling GMOs in foods, requiring that the re-
tail packaging contain the clear and conspicu-
ous words ‘Produced with Genetic Engineer-
ing’ and redefining the FDA’s use of the term 
‘natural food’ to include food that has not 
been genetically engineered. However, the 
Connecticut statute provided that the law 
would not take effect until the passage of sim-
ilar legislation by four additional Northeast 
states, with a total aggregate population of 
more than 20 million, one of which borders 
Connecticut (Connecticut General Statutes, 
2013). Soon after, Maine passed a similar law 
requiring genetically engineered food and 
seed stock to be conspicuously labeled as 
‘Produced with Genetic Engineering’ and 
prohibiting such foods from being labeled as 
‘natural’. But the Maine statute also contained 
a ‘trigger’ clause providing that at least five 
contiguous states must pass comparable laws 
(Maine Legislature, 2013). Numerous other 
states had launched their own labeling bills, 
some of which were defeated (e.g. California) 
but were slated to be reintroduced by advo-
cates (Center for Food Safety, no date).
The most successful and definitive of these 
state laws was passed in Vermont (Vermont 
General Assembly, 2014) in May 2014, with 
an accompanying rule, ‘Consumer Protec-
tion Rule 121’, which like the previous states 
required that food entirely or partially pro-
duced with genetic engineering be labeled as 
such. The law applied to raw agricultural prod-
ucts such as corn and squash as well as pro-
cessed foods like crackers, soda and cereals. 
Its comprehensive scheme applied to produc-
ers, processors, distributors and retailers. 
Exemptions included processed foods that 
would otherwise have been subject to the la-
beling requirement due to containing one or 
more materials that have been produced 
with genetic engineering, in which the ge-
netically engineered materials in the aggre-
gate do not account for more than 0.9% of 
the total weight of the processed food. 
The Vermont law was set to go into effect on 
1 July 2016, when the biotechnology indus-
try intervened and succeeded in pushing 
Congress to cut short the state initiatives.
The National Bioengineered Food Disclo-
sure Standard (United States, 2016), pejora-
tively called the DARK (‘Denying Americans 
the Right to Know’) Act like a previous ver-
sion that had been defeated, was signed into 
law by President Obama on 29 July 2016. It 
amended the Agricultural Marketing Act of 
1946 to require the Secretary of Agriculture 
to ‘establish a national mandatory bioengi-
neered food disclosure standard with respect 
to any bioengineered food and any food that 
may be bioengineered’ (Section 293). In a 
blow to community activists and consumer 
groups, this statute pre-empted the states 
from passing their own – and Vermont from 
implementing its enacted – GMO labeling 
laws. Furthermore, the USDA sent preemp-
tion letters to the governor of every state 
(USDA, no date(a)). If challenged in court, 
however, this may be held to be an improper 
use of preemption, as the federal law cur-
rently does not present the requisite charac-
teristics of a comprehensive regulatory 
scheme. While technically a law requiring 
labeling, it appears on its face to be so mini-
mal and likely ineffective in its conveyance 
of information to the consumer that it may 
be determined to lack adequate and mean-
ingful labeling and thus violate the right of 
informed consent and effective choice.
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With respect to food, the federal statute 
defines the term ‘bioengineering’ as a food 
‘that contains genetic material that has been 
modified through in vitro recombinant de-
oxyribonucleic acid (DNA) techniques . . . for 
which the modification could not otherwise 
be obtained through conventional breeding 
or found in nature’ and limits its scope to 
foods that are already subject to labeling re-
quirements under the Federal Food, Drug, 
and Cosmetic Act, the Federal Meat Inspec-
tion Act, the Poultry Products Inspection Act 
and the Egg Products Inspection Act, as well 
as the predominance of its ingredients (Sec-
tions 291 and 292). Although labeling for 
these substances in food will be mandatory, 
it gives manufacturers a choice of the disclo-
sure on the package via ‘text, symbol, or 
electronic or digital link’ (e.g. QR code ac-
cessed with a smartphone) (Section 293(b)
(2)(D)). Small food manufacturers can choose 
to comply instead by placing a telephone 
number accompanied by appropriate lan-
guage to indicate that the phone number 
provides access to additional information 
and an internet website with disclosure of 
bioengineering ingredients; the telephone 
number disclosure must only state, ‘Call for 
more food information’ (Sections 293(b)(2)
(F)(ii) and 293(d)(1)(B)).
Critics of this new law note that it does 
not specifically mandate that manufacturers 
have to post a label or warning that the food 
contains GMOs. Consumer groups have ex-
pressed concern that manufacturers will 
choose the method that gives the least 
amount of information or makes it difficult 
for consumers to ascertain this information 
in a timely and effective way in order to be 
able to make a choice before their purchas-
ing decision (Nat, 2016; Begley, 2017). This 
problem will be exacerbated by technological 
limitations if the consumer does not have 
cell service, a phone capable of reading a QR 
code, or the comfort level and knowledge to 
do so (Justlabelit, no date; Center for Food 
Safety, 2017). A national survey confirmed 
that 88% of American voters prefer GMO la-
beling printed on the package over bar codes 
that would be scanned by a smartphone app 
(Melman Group, 2015). In addition, consum-
er advocates object to the narrow definition 
of ‘bioengineered’ and scope of the labeling 
advocated by the industry, urging instead 
that ‘all foods produced through genetic 
engineering are labeled; including those 
derived from genetically engineered sourc-
es, such as highly refined sugars and oils 
and processed corn and soy ingredients’ 
(McCann, 2017, n.p.). Moreover, any thresh-
old set by the USDA should be consistent 
with international standards – the manda-
tory disclosure of 0.9% by individual GE in-
gredient (2017, n.p.).
Unlike previous statutes that put food 
 labeling in the purview of the FDA, the 
law designated the Agricultural Marketing 
 Service (AMS) of the USDA as the agency 
responsible for promulgating additional regu-
lation that would fill in the details to establish 
a ‘national mandatory system for disclosing 
the presence of bioengineered material’ 
(USDA, no date(a)). The USDA has formed a 
working group to develop a timeline for rule-
making and posted questions on its website 
in the summer of 2017 to seek input on a 
series of issues left open by the legislation to 
aid in its drafting of the rules. These ques-
tions include the scope, threshold levels and 
definitions of a ‘bioengineered food’; the 
type of text, symbol or digital/electronic 
link that should be designated ‘if a manufac-
turer chooses to use’ it; alternatives for ‘very 
small or small packages’; and definitions for 
the stated exclusions, such as ‘small’ and 
‘very small manufacturers’, ‘restaurants and 
similar retail food establishments’ (USDA, 
no date(b)). AMS received over 112,000 re-
sponses from individuals and organizations 
to be used in its drafting of the proposed 
rule, issued with an additional public com-
ment period.
The USDA also commissioned a study ‘to 
identify potential technological challenges 
that may impact whether consumers would 
have access to the bioengineering disclosure 
through electronic or digital disclosure meth-
ods’ and published the results on 7 Septem-
ber 2017 (USDA, 2017b). Among its most 
significant findings was the fact that 85% of 
consumers experienced technical challenges 
when using mobile apps for scanning digital 
links: ‘In addition, most apps contain adver-
tisements that confuse consumers and run 
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counter to how the Law requires disclosure 
when regulations are finalized and imple-
mented’ (2017b, p. 4). Pursuant to the law, 
the USDA is required to have the final rules 
in place by 29 July 2018, two years after the 
passage of the legislation.
In view of prospective future court chal-
lenges, it would be prudent for the USDA to 
take the opportunity to strengthen labeling 
requirements to a level akin to Vermont and 
other state initiatives or international stand-
ards. The Vermont Attorney General’s Office 
has already announced its intention to ‘take 
an active role as the labeling fight shifts 
from the legislative process in Congress to 
the regulatory process at the USDA . . . We 
will work hard to give consumers the same 
access to information, in plain English, that 
they had under Vermont’s law’ (2016, n.p.). 
Pressure will be wielded by consumers, anti- 
GMO groups and other stakeholders to deter-
mine if this will be only the first step in a 
comprehensive and effective mandatory 
federal labeling scheme or a temporary de-
feat for states that will ultimately prevail 
over federal obstructionism. One way or an-
other, the US government must respond to 
the increasing crescendo of the public outcry 
for transparency and disclosure in the debate 
over food safety. Hopefully these governmen-
tal agencies will be guided by their charge and 
uphold their duty to the public to take into 
account consumer concerns regarding labeling 
and to make paramount the safety of the food 
supply for the average American consumer.
A Framework that Addresses these 
Ethical Tensions
In light of ethical concerns and individuals’ 
comfort levels in assessing whether the risks 
are acceptable, American consumers should not 
be bound to accept the possible consequences 
of GM foods without their knowledge and 
consent. With scientific uncertainty about 
the risks of consuming GM foods unlikely to 
be resolved in the near future, ethical con-
cerns should be the paramount factor in de-
termining a model of labeling, segregating 
and monitoring for GM foods.
Reflecting on the ethical tensions that bi-
otechnology creates prompts one to consid-
er questions that should be raised and 
utilized to construct a more appropriate 
regulatory response. The current regulatory 
framework is inadequate because it predates 
the advent of this technology and forces reg-
ulators to conform substances created 
through a novel process into preexisting and 
longstanding notions of safety and efficacy. 
Better public policy would result from 
approaching this area from an alternative 
perspective. Under what conditions do con-
sumers have a right to know the process by 
which their food has been produced? The US 
already requires labeling to inform consum-
ers about some food production cases (e.g. 
irradiation). Given the uniqueness of bio-
technology and its potential for harm, 
should this change the way we think about 
the right to know and implore us to answer 
this question in the affirmative?
The way of approaching market approvals 
and labeling requirements in the past has 
been to focus only on the composition and 
safety of the product itself without consid-
ering the potential risk inherent in the tech-
nology. Biotechnology is so fundamentally 
different that it forces us to rethink that ap-
proach. Biotechnology raises issues separate 
from whether to label the product as to the 
presence of a particular ingredient or lack 
thereof, which has been the traditional ap-
proach of the FDA. Genetic engineering of 
food also goes beyond the existing criteria 
for labeling of the potential for harm embod-
ied by the concept of ‘substantial equiva-
lence’, regardless of whether the product 
itself is or is not different. Under the current 
FDA policy, if a genetically engineered prod-
uct does not appear to be substantially dif-
ferent than its conventional counterpart, no 
special labeling or animal testing is required. 
‘From FDA’s perspective, biotechnologically- 
produced products are seen as substantially 
equivalent to conventional food products 
because, in the agency’s view, there is no sci-
entific basis to presuppose that biotech 
foods are more risky or substantially differ-
ent from other food products’ (Strauss, 2006, 
p. 183). However, there is no definition
provided in the regulations for substantial 
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equivalence or clear guidelines stipulating 
what to examine and how similar the items 
in question should be; this concept has been 
discredited in Europe as unscientific and not 
adequate to justify a lack of safety assess-
ments (Strauss, 2006). Biotechnology is so 
extraordinary that there are many unknowns 
and scientific uncertainty, with potential 
risks inherent in the technology itself. 
This innovation calls for a new way of think-
ing because it would be inappropriate for 
regulators to impose an existing framework 
on it. Policy makers should recognize this 
matter as unique due to the unknowns and 
possible risks.
The issue of risk is made even more com-
pelling due to the fact that science has not 
yet advanced to measure and assess these 
risks using standard risk assessment tech-
niques. Thus policy makers cannot turn to 
science alone to provide the answers to the 
pressing questions. A more precautious poli-
cy could create the proper incentives for the 
development of more advanced risk assess-
ment procedures, as well as improved detec-
tion methods and long-term studies of safety. 
Moreover, a more prudent policy with great-
er emphasis on public safety concerns would 
be consistent with the government’s recent 
proactive approach towards food safety em-
bodied in the Food Safety Modernization 
Act (Strauss, 2011). Until such time as these 
risks can be ascertained with a higher degree 
of certainty, consumers of these products 
should be given a choice and allowed to 
weigh their own personal comfort levels in 
their purchase and consumption decisions. 
In view of this scientific uncertainty, effec-
tive labeling should be an important compo-
nent of the revised regulatory framework, 
along with an education campaign as to the 
meaning and significance of these GE desig-
nations.
This discussion relates to a more funda-
mental question: when a new technology is 
introduced, when do people have the right 
to be informed and what do they have a right 
to be informed about (e.g. that the product 
was made through this method)? This con-
cern goes beyond a focus on the potential for 
harm. As the Terminator gene illustrates, 
there is no limit to what might be developed 
through genetic engineering because bio-
technology is so profoundly different from 
traditional crop and animal breeding prac-
tices. As a consequence, society needs to de-
velop a different way of looking at it – at the 
very least labeling and educating the public – 
and ultimately introducing a new regulatory 
scheme so that as the science and technol-
ogy develops, new inventions will be in-
corporated into that scheme. For example, 
requiring better detection methods and risk 
assessment for the approval process would 
both provide incentives to develop that new 
technology and guide the future direction of 
the science.
A consideration of these issues highlights 
the fact that ethical principles must shape the 
solution for the treatment of biotechnology 
food products. The incorporation of ethics 
into policy development should involve all 
stakeholders: farmers, consumers, the envi-
ronment, underprivileged populations and 
the agricultural biotechnology industry. 
Recognition of the inherent conflicts of in-
terest also necessitates a more active and 
independent role of regulatory agencies in 
relation to the biotechnology companies. An 
important part of this framework would be 
clear and comprehensive labeling, which is 
essential for informed consumer choice, as 
well as a sharing of information and educa-
tion on the science, including all potential 
and discovered risks to human health and 
the environment.
A group of scientific experts identified 
three important components for risk manage-
ment: impact assessment, public awareness/
participation and the design of regulatory 
systems. Above all is involvement of the 
public: ‘It is not possible to overstate the 
importance of the public’s contribution to 
effective decision making, as well as the im-
portance of public awareness, within the 
context of government decisions on matters 
and activities affecting the environment’ 
(Prakash et al., 2011, p. 6). Under this analy-
sis, disclosure and transparency should ex-
tend beyond public access to governmental 
documents and processes:
[T]here are other mechanisms by which 
public awareness and access to information 
can be encouraged, including product 
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labeling, food safety standards, and general 
consumer protection laws, all of which are 
designed to foster awareness and communicate  
public preferences to the commercial 
proponents of GMOs in a way that will get 
their attention. (2011, p. 6)
In order to be effective, such labeling must 
be ‘accurate, specific, and clearly expressed 
in understandable language, unbiased, and 
based on full disclosure of the relevant facts 
by the GMO proponents’ (Prakash et al., 
2011, p. 6).
The WHO study also recognized the need 
and responsibility for communicating risks 
to the public so that ‘ethical components of 
food-safety decisions are clearly identified 
as early in the process as possible’ and ‘val-
ue-laden choices made by risk managers are 
made in an open, participatory process that 
respects the rights and roles of all stakehold-
ers’ (2005, p. 56).
Conclusion
In view of the most recent federal labeling 
statute in this area, the predominant query 
to consider may be the following: Do the cur-
rent regulations, or lack of adequate and 
meaningful labeling, violate our responsibil-
ities to others by not allowing them a choice 
as to whether they knowingly and willingly 
assume the risks of ingesting these geneti-
cally engineered substances? Efforts to quell 
the public outcry by preempting state and 
local community labeling initiatives would 
be better directed to incorporating these de-
sires into the international policy arena.
The ethical implications are clear, followed 
by the expectation that the legal system 
should fill in the ethical gap as it has done in 
so many other areas and, at the very least, 
require meaningful labeling, pre-market 
approval and monitoring of GMOs in food 
products and ingredients. Fully informing 
the public and transparency in the regulatory 
process are the keys. Incorporating ethical 
tensions in the policy and regulation arena 
requires US policy makers to respond appro-
priately to the consumer demands that led 
to grassroots efforts and embrace rather 
than suppress these initiatives. Mandato-
ry labeling that clearly and effectively dis-
closes genetically engineered ingredients 
and processes would be the responsible 
next step.
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